Commentary|Videos|November 20, 2026

Dr Desjardins on Recent Developments Reshaping Brain Cancer Care

Fact checked by: Jonah Feldman

Annick Desjardins, MD, discusses the importance of the reclassification of brain tumors and efforts to enable immunotherapy to bypass the blood-brain barrier.

Improved molecular classification and a better understanding of the immune environment in brain tumors are changing how patients with brain cancer are treated, according to Annick Desjardins, MD, neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke Cancer Institute and professor of neurosurgery and neurology at the Duke University School of Medicine. She described both as the most meaningful recent developments in the field.

In the past, many patients were all diagnosed with glioblastoma multiforme and grouped together, Desjardins said, even though outcomes varied widely. She told patients that some would do very poorly and others much better, without a clear way to predict which.

The 2021 World Health Organization (WHO) classification of brain tumors changed that by defining subcategories of gliomas. Clinicians can now better identify which patients are likely to do better, understand why, and find the genetic alterations linked to worse outcomes. Desjardins said these discoveries make it possible to match patients with more specific targeted therapies. Previously, patients received the same treatment in the hope that it would work.

The second development involves immunotherapy. Desjardins said researchers now better understand how the immune system behaves in brain tumors, including the immunosuppressive environment surrounding them. Conventional immunotherapies that work in other cancers often fail to cross the blood-brain barrier at high enough levels. Researchers are therefore exploring other strategies, including direct delivery of immunotherapy to the tumor, approaches involving the draining lymph nodes, and technologies such as focused ultrasound to open the blood-brain barrier.

Desjardins said these discoveries are now making immunotherapy available to patients with brain tumors.


Related to this article